| Drug major Kopran has received approval from the US patent office for its new chemical entity (NCE) - KNC-6 filed in September 2001.
|
| |
| KNC-6 is a novel dual action anti-ulcerant having significant anti-secretory and cytoprotective properties with quick onset of action.
|
| |
| The company has also filed patent application for KNC-6 in 30 other countries including Japan, Australia, Canada and the European countries.
|
| |
| KNC-6 is one of the NCEs identified by the company for focus besides KNC-1206, a laxative. The new molecules are in the pre-clinical stage.
|
| |
| The company said in a press release, “The company’s drug discovery programme has been designed on a basic platform technology by using bioactive polymers. The process patent for this technology has been filed under the Paris Convention Treaty.”
|
| |
| The company’s research & development (R&D) activitivities are undertaken through its 100 per cent subsidiary Kopran Research.
|
| |
| The company’s R&D is focussed on NCEs, dosage forms, biotechnology and synthesis and has filed for 20 process patents and 4 product patents.
|
| |
| Kopran is also looking at various opportunities including strategic collaboration and out-licensing of the NCEs with foreign partners.
|
| |
| Kopran, a leading amoxycillin producer, has enhanced its focus on formulations and over-the-counter (OTC) products.
|
| |
| The company’s exports focus has also been sharpened. It has been affected by the continuous fall in prices due to increased competition in the bulk drugs segment.
|
| |
| The therapeutic segments where the company has a presence include cardiovascular, antibiotics, pain management, gastrointestinal and respiratory.
|
| |
| The company’s leading products include Aten (anti-hypertensive), Vent (anti-asthmatic), Tini (anti-amoebic) and Lokit (anti-ulcer). |
| |
Content Guide
